|K-rasFSF-G12D mice allow conditional, sequential expression of the oncogenic G12D mutant form of Kras (v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog) following Flp recombinase-mediated excision of a FRT-flanked Stop cassette.|
Type Congenic; Mutant Strain; Targeted Mutation; Additional information on Genetically Engineered and Mutant Mice. Visit our online Nomenclature tutorial. Additional information on Congenic nomenclature. Species laboratory mouse Donating Investigator Dr. Tyler Jacks, Massachusetts Institute of Technology
This K-rasFSF-G12D strain carries an FRT-flanked Stop cassette in intron 1 of the Kras (v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog) gene. Flp recombinase-mediated excision of the Stop cassette enables conditional, sequential expression of the oncogenic G12D mutant form of the gene. When recombined in various tissues, the phenotype is anticipated to be the same as that seen with tissue-specific Cre-mediated recombination in the K-ras LSL strain (see Stock No. 008180).
An Frt-STOP-Frt (FSF) cassette was inserted into the Sal I site in intron 1 of the targeted gene, which also carries a G->D point mutation in codon 12. A puromycin resistance gene is flanked by FRT sites, 5' of the STOP element, and reads in the opposite orientation to that of the targeted locus. The mutation was created using C57BL/6-derived v26.2 embryonic stem (ES) cells. Subsequent crosses with other strains (major alleles now bred away) were carried out. This line was backcrossed to C57BL/6J for 11 generations by the donating lab.
|Wild-type from the colony|
|Considerations for Choosing Controls|
Strains carrying Krastm5Tyj allele
008653 B6;129-Krastm5Tyj/JView Strains carrying Krastm5Tyj (1 strain)Strains carrying other alleles of Kras
002674 129-Krastm1Tyj/J 008185 129S/Sv-Krastm3Tyj/J 008180 129S/Sv-Krastm4Tyj/J 008179 B6.129S4-Krastm4Tyj/J 019104 B6N.Cg-Krastm4Tyj/CjDswJView Strains carrying other alleles of Kras (5 strains)
View Related Disease (OMIM) TermsRelated Disease (OMIM) Terms provided by MGI
- Potential model based on gene homology relationships. Phenotypic similarity to the human disease has not been tested.Bladder Cancer (KRAS)
Breast Cancer (KRAS)
Cardiofaciocutaneous Syndrome 2; CFC2 (KRAS)
Gastric Cancer, Hereditary Diffuse; HDGC (KRAS)
Lung Cancer (KRAS)
Noonan Syndrome 3; NS3 (KRAS)
Pancreatic Cancer (KRAS)
Schimmelpenning-Feuerstein-Mims Syndrome; SFM (KRAS)
View Mammalian Phenotype TermsMammalian Phenotype Terms provided by MGIassigned by genotype
The following phenotype information may relate to a genetic background differing from this JAX® Mice strain.
Krastm5Tyj/Kras+involves: 129S4/SvJae * C57BL/6 (conditional)
- increased lung tumor incidence
- following administration of a flp-expressing adenovirus or lentivirus (MGI Ref ID J:172206)View Research Applications
|Allele Name||targeted mutation 5, Tyler Jacks|
|Allele Type||Targeted (Floxed/Frt)|
|Common Name(s)||K-ras FSF; K-rasFSF-G12D;|
|Mutation Made By||Dr. Tyler Jacks, Massachusetts Institute of Technology|
|Strain of Origin||C57BL/6|
|ES Cell Line Name||V26.2|
|ES Cell Line Strain||C57BL/6|
|Gene Symbol and Name||Kras, v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog|
|Gene Common Name(s)||AI929937; C-K-RAS; CFC2; K-RAS2A; K-RAS2B; K-RAS4A; K-RAS4B; K-ras; KI-RAS; KRAS1; KRAS2; Kirsten rat sarcoma oncogene 2, expressed; Kras-2; Kras2; NS; NS3; RASK2; c-Ki-ras; expressed sequence AI929937; p21;|
|Molecular Note||This allele has a FRT-STOP-FRT cassette in intron 1 of the oncogenic form of the v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog gene (G12D mutation). Before expression of enhanced Flp (FLPe) or mouse codon-optimized FLP (FLPo) recombinase, the allele is not expressed due to the transcriptional STOP cassette. Following introduction of the recombinase, the FRT sites are recombined and the STOP cassette is removed resulting in expression of the mutant Kras transcript and protein. [MGI Ref ID J:140469]|
Jacks T. 2008. Generation of a conditional mutant Kras allele MGI Direct Data Submission :. [MGI Ref ID J:140469]
Lee CL; Moding EJ; Huang X; Li Y; Woodlief LZ; Rodrigues RC; Ma Y; Kirsch DG. 2012. Generation of primary tumors with Flp recombinase in FRT-flanked p53 mice. Dis Model Mech 5(3):397-402. [PubMed: 22228755] [MGI Ref ID J:180576]
Snyder EL; Watanabe H; Magendantz M; Hoersch S; Chen TA; Wang DG; Crowley D; Whittaker CA; Meyerson M; Kimura S; Jacks T. 2013. Nkx2-1 represses a latent gastric differentiation program in lung adenocarcinoma. Mol Cell 50(2):185-99. [PubMed: 23523371] [MGI Ref ID J:198227]
Youn JI; Kumar V; Collazo M; Nefedova Y; Condamine T; Cheng P; Villagra A; Antonia S; McCaffrey JC; Fishman M; Sarnaik A; Horna P; Sotomayor E; Gabrilovich DI. 2013. Epigenetic silencing of retinoblastoma gene regulates pathologic differentiation of myeloid cells in cancer. Nat Immunol 14(3):211-20. [PubMed: 23354483] [MGI Ref ID J:193480]
Breeding & Husbandry When maintained as a live colony, heterozygotes may be bred. Homozygotes die during embryogenesis.
This strain is currently Awaiting Transfer from the Donor.View All Strains Awaiting Transfer from the Donor, In Progress and On Hold
|Wild-type from the colony|
|Considerations for Choosing Controls|
|Control Pricing Information for Genetically Engineered Mutant Strains.|
For Licensing and Use Restrictions view the link(s) below:
- Notice to customers in Canada.
- Use of MICE by companies or for-profit entities requires a license prior to shipping.
- Use of MICE by companies or for-profit entities requires a license.
MICE, PRODUCTS AND SERVICES ARE PROVIDED “AS IS”. JACKSON EXTENDS NO WARRANTIES OF ANY KIND, EITHER EXPRESS, IMPLIED, OR STATUTORY, WITH RESPECT TO MICE, PRODUCTS OR SERVICES, INCLUDING ANY IMPLIED WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, OR ANY WARRANTY OF NON-INFRINGEMENT OF ANY PATENT, TRADEMARK, OR OTHER INTELLECTUAL PROPERTY RIGHTS.
In case of dissatisfaction for a valid reason and claimed in writing by a purchaser within ninety (90) days of receipt of mice, products or services, JACKSON will, at its option, provide credit or replacement for the mice or product received or the services provided.
In no event shall JACKSON, its trustees, directors, officers, employees, and affiliates be liable for any causes of action or damages, including any direct, indirect, special, or consequential damages, arising out of the provision of MICE, PRODUCTS or services, including economic damage or injury to property and lost profits, and including any damage arising from acts or negligence on the part of JACKSON, its agents or employees. Unless prohibited by law, in purchasing or receiving MICE, PRODUCTS or services from JACKSON, purchaser or recipient, or any party claiming by or through them, expressly releases and discharges JACKSON from all such causes of action or damages, and further agrees to defend and indemnify JACKSON from any costs or damages arising out of any third party claims.
MICE and PRODUCTS are to be used in a safe manner and in accordance with all applicable governmental rules and regulations.
The foregoing represents the General Terms and Conditions applicable to JACKSON’s MICE, PRODUCTS or services. In addition, special terms and conditions of sale of certain MICE, PRODUCTS or services may be set forth separately in JACKSON web pages, catalogs, price lists, contracts, and/or other documents, and these special terms and conditions shall also govern the sale of these MICE, PRODUCTS and services by JACKSON, and by its licensees and distributors.
Acceptance of delivery of MICE, PRODUCTS or services shall be deemed agreement to these terms and conditions. No purchase order or other document transmitted by purchaser or recipient that may modify the terms and conditions hereof, shall be in any way binding on JACKSON, and instead the terms and conditions set forth herein, including any special terms and conditions set forth separately, shall govern the sale of MICE, PRODUCTS or services by JACKSON.